Contineum Therapeutics, Inc.
CTNM
$4.62
$0.245.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 30.99% | 13.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.39% | 18.55% | |||
| Operating Income | -31.39% | -18.55% | |||
| Income Before Tax | -41.86% | -13.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -41.86% | -13.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -41.86% | -13.96% | |||
| EBIT | -31.39% | -18.55% | |||
| EBITDA | -31.44% | -18.63% | |||
| EPS Basic | -41.40% | -3.45% | |||
| Normalized Basic EPS | -41.38% | -3.44% | |||
| EPS Diluted | -41.05% | -2.56% | |||
| Normalized Diluted EPS | -41.38% | -3.44% | |||
| Average Basic Shares Outstanding | 0.33% | 10.17% | |||
| Average Diluted Shares Outstanding | 0.33% | 10.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||